



TITLE:

Oral Administration of Apple Procyanidins
Ameliorates Insulin Resistance via
Suppression of Pro-inflammatory Cytokines
Expression in Liver of Diabetic ob/ob Mice

AUTHOR(S):

Ogura, Kasane; Ogura, Masahito; Shoji, Toshihiko; Sato,
Yuichi; Tahara, Yumiko; Yamano, Gen; Sato, Hiroki; ...
Fujimoto, Shimpei; Inagaki, Nobuya; Nagashima, Kazuaki

CITATION:

Ogura, Kasane ...[et al]. Oral Administration of Apple Procyanidins Ameliorates Insulin Resistance via Suppression of Pro-inflammatory Cytokines Expression in Liver of Diabetic ob/ob Mice. *Journal of Agricultural and Food Chemistry* 2016, 64(46): 8857-8865

ISSUE DATE:

2016-11-23

URL:

<http://hdl.handle.net/2433/217455>

RIGHT:

This document is the Accepted Manuscript version of a Published Work that appeared in final form in *Journal of Agricultural and Food Chemistry*, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see <http://dx.doi.org/10.1021/acs.jafc.6b03424>; The full-text file will be made open to the public on 23 Nov. 2017 in accordance with publisher's 'Terms and Conditions for Self-Archiving'; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。; This is not the published version. Please cite only the published version.

JOURNAL OF
AGRICULTURAL AND
FOOD CHEMISTRY

Subscriber access provided by KYOTO UNIV

Article

Oral Administration of Apple Procyanidins Ameliorates
Insulin Resistance via Suppression of Pro-inflammatory
Cytokines Expression in Liver of Diabetic ob/ob MiceKasane Ogura, Masahito Ogura, Toshihiko Shoji, Yuichi Sato, Yumiko Tahara,
Gen Yamano, Hiroki Sato, Kazu Sugizaki, Naotaka Fujita, Hisato Tatsuoka, Ryota
Usui, Eri Mukai, Shimpei Fujimoto, Nobuya Inagaki, and Kazuaki Nagashima*J. Agric. Food Chem.*, **Just Accepted Manuscript** • DOI: 10.1021/acs.jafc.6b03424 • Publication Date (Web): 28 Oct 2016Downloaded from <http://pubs.acs.org> on October 30, 2016

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Publications

Journal of Agricultural and Food Chemistry is published by the American Chemical Society, 1155 Sixteenth Street N.W., Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

1 **Oral Administration of Apple Procyanidins Ameliorates Insulin Resistance via**
2 **Suppression of Pro-inflammatory Cytokines Expression in Liver of Diabetic ob/ob**
3 **Mice**

4

5 Kasane Ogura[†], Masahito Ogura[†], Toshihiko Shoji[‡], Yuichi Sato[†], Yumiko Tahara[†], Gen
6 Yamano[†], Hiroki Sato[†], Kazu Sugizaki[†], Naotaka Fujita[†], Hisato Tatsuoka[†], Ryota
7 Usui[†], Eri Mukai[§], Shimpei Fujimoto^{//}, Nobuya Inagaki[†], Kazuaki Nagashima^{†*}

8

9 [†] Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine,
10 Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

11 [‡] NARO Institute of Fruit Tree Science, 2-1 Fujimoto, Tsukuba, Ibaraki
12 305-8605, Japan

13 [§] Laboratory of Medical Physiology and Metabolism, Department of Biomedical
14 Sciences, Collage of Life Science, Ritsumeikan University,
15 1-1-1 Noji-higashi, Kusatsu, Shiga 525-8577, JAPAN

16 ^{//} Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School,
17 Kochi University, 185-1, Kohasu, Oko-cho, Nankoku, Kochi 783-8505, Japan

18

ABSTRACT

Procyanidins, the main ingredient of apple polyphenols, are known to possess anti-oxidative and anti-inflammatory effects associated closely with the pathophysiology of insulin resistance and type 2 diabetes. We investigated the effects of orally administered apple procyanidins (APCs) on glucose metabolism using diabetic ob/ob mice. We found no difference in body weight or body composition between APCs-treated and untreated mice. 4-week oral administration of APCs containing water (0.5% w/v) ameliorated glucose tolerance, insulin resistance, and hepatic gluconeogenesis in ob/ob mice. APCs also suppressed the increase of pancreatic β -cell. Insulin-stimulated Akt phosphorylation was significantly enhanced, pro-inflammatory cytokine expression levels were significantly decreased, and c-Jun N-terminal kinase (JNK) phosphorylation was down-regulated in the liver of those APCs-treated mice. In conclusion, APCs ameliorate insulin resistance by improving hepatic insulin signaling through suppression of hepatic inflammation in ob/ob mice, which may be a mechanism of possible beneficial health effects of APCs in disturbed glucose metabolism.

Keywords: apple procyanidins, insulin resistance, inflammation, ob/ob mouse

37

38 ■INTRODUCTION

39 Insulin resistance induced by obesity readily develops into type 2 diabetes and leads
40 to elevated risk of cardiovascular disease. The pathogenesis of type 2 diabetes is
41 characterized by two major features, insulin resistance and impaired insulin secretion.
42 If insulin demand due to insulin resistance is over the capacity of pancreatic β -cells,
43 blood glucose homeostasis cannot be maintained, leading to chronic hyperglycemia.
44 Reducing insulin resistance is therefore clinically important for the prevention and
45 management of type 2 diabetes.

46 The mechanism of insulin resistance is still unclear. Insulin resistance is reported to
47 be associated with a state of chronic and low-grade inflammation in insulin target
48 tissues including adipose tissue, liver and skeletal muscle. Tumor necrosis factor- α
49 (TNF- α), a pro-inflammatory cytokine produced from accumulated fat, activates
50 various signaling cascades, including c-Jun N-terminal kinase (JNK). JNK leads to
51 serine phosphorylation of insulin receptor substrate (IRS)-1 and 2, and consequently
52 induces insulin resistance.¹ Oxidative stress also activates the JNK pathway and
53 induces insulin resistance.²

54 Epidemiological studies suggest that consumption of fruits and vegetables reduces

55 the risk of developing type 2 diabetes.^{3,4} The benefits of fruits and vegetables have
 56 been attributed to their dietary fiber and various phytochemicals, such as polyphenol.
 57 Apple is one of the most commonly consumed fruits in the world. Apple polyphenols
 58 are known to have various physiological effects including antioxidant activity,⁵
 59 anti-inflammation activity,⁶ and anti-tumor activity.⁷

60 Apple procyanidins (APCs) are the main ingredient of apple polyphenols⁸ and
 61 consist of flavanol units such as (+)-catechin and (–)-epicatechin, which are linked
 62 together through 4→8 and 4→6 interflavonoid bonds, and have many isomeric forms
 63 depending on the extent of polymerization and the nature of their constituent units
 64 (Figure S1). Recent research has indicated that APCs have various beneficial effects on
 65 health, including anti-aging effects in *Caenorhabditis elegans*,⁹ an inhibitory effect on
 66 triglyceride absorption through inhibition of pancreatic lipase activity in mouse and
 67 human,¹⁰ and anti-inflammatory and immunomodulatory effects on intestinal epithelial
 68 cells.¹¹

69 However, there are few reports regarding ingestion of APCs and risk of type 2
 70 diabetes. In this study, we investigated the effects of APCs on glucose metabolism
 71 using model mice for obesity and type 2 diabetes. Our findings may lead to a strategy
 72 for development of therapeutic agents for impaired glucose tolerance and type 2

73 diabetes.

74

75 ■ MATERIALS AND METHODS

76 Preparation of apple polyphenol extracts

77 The procyanidin fraction was prepared from apple (*Malus pumila* cv. Fuji) by
78 preparative column chromatography with the method of previous study.¹² Briefly, the
79 apple polyphenol fraction was prepared from apple juice using the preparative column
80 with aromatic synthetic adsorbents, Sepabeads SP-850 (Mitsubishi Kasei Co., Ltd.,
81 Japan). Apple polyphenol extracts were lyophilized, and the powder obtained was
82 dissolved in distilled water and adjusted to pH 6.5 with 5N NaOH. The sample was
83 applied to a Diaion HP-20ss (Mitsubishi Kasei Co., Ltd., Japan) column, and after
84 rinsing the column with distilled water, the procyanidin fraction was eluted with 25%
85 ethanol. Finally, the eluate was concentrated by rotary evaporation at 45°C and
86 lyophilized as the APCs fraction. APCs were analyzed using by reversed-phase HPLC
87 equipped with an LC-10AD VP pump (Shimadzu, Kyoto, Japan), an SIL-10AD VP
88 autosampler (Shimadzu), and a Inertsil ODS-3 (GL Sciences Inc., Tokyo, Japan)
89 reversed-phase column (150 x 4.6 mm i.d.) at 40°C. Mixtures of 10 mM KH₂PO₄
90 solution (adjusted to pH 1.8 with H₃PO₄) and methanol was used as the mobile phase

91 [mobile phase A, 10 mM KH_2PO_4 :MeOH (8:2) and mobile phase B, 10 mM
92 KH_2PO_4 :MeOH (5:5)] were used as the mobile phases with a flow rate of 1.0 ml/min.
93 Detection was performed using a SPD-10A VP UV-vis detector (Shimadzu) at 280 nm.
94 For the first 10 min, the initial eluent used was 0% mobile phase B, followed by a
95 linear gradient from 100% mobile phase B for 40 min; subsequently the concentration
96 was held at 100% mobile phase B for 15 min and then returned to the initial conditions.
97 This fraction did not include phloretin glucoside (phlorizin) or chlorogenic acid
98 (Figure 1). The former has a blood glucose lowering effect by inhibiting sodium
99 glucose cotransporter (SGLT1 and SGLT2),¹³ and the latter has several beneficial
100 biological properties including blood pressure lowering and anti-oxidative effects.^{14,15}

101

102 Mice

103 5-week-old male B6.Cg-Lepob/J mice (C57BL/6J background) were purchased
104 from Charles River Japan Inc. (Kanagawa, Japan). The phenotype is obese and insulin
105 resistance but hyperglycemia is not so severe. They were divided into two groups: an
106 APCs-treated and an untreated group. The mice were housed in individual under
107 controlled environment at 23°C and 12-hour light/dark cycle with free access to water
108 and a commercial nonpurified diet (MF, Oriental Yeast Co., Tokyo, Japan). All animal

109 experiments were approved by the Kyoto University Animal Care Committee.
110 Beginning at 8 weeks of age, mice were administered APCs dissolved in drinking
111 water (0.5%, w/v) ad libitum for 4 weeks. Body weight and food intake were measured
112 once every week and water intake was measured every day. During continuation of the
113 APCs administration to 16 weeks of age, insulin tolerance test (ITT), oral glucose
114 tolerance test (OGTT), and pyruvate tolerance test (PTT) were performed.

115

116 **Measurement of energy expenditure**

117 Energy expenditure of the mice at the age of 16 weeks was measured for 48 hours
118 using indirect calorimetry. Oxygen consumption and CO₂ production were determined
119 every 5 min in an open chamber with the mass spectrometry-based O₂ and
120 CO₂ analyzer ARCO-2000 (ARCO system, Chiba, Japan). Oxygen consumption was
121 normalized by lean body mass.

122

123 **Measurement of blood glucose, oral glucose tolerance test and insulin tolerance** 124 **test**

125 After 4 weeks administration of water with or without 0.5% APCs, APCs-treated
126 and untreated ob/ob mice were fasted overnight for 16 h, and received an oral dose of

127 1 g/kg glucose. Blood glucose levels and serum insulin concentrations were measured
128 at 0, 15, 30, 60, and 120 min after oral injection by the glucose oxidase method (Sanwa
129 Kagaku Kenkyusho, Nagoya, Japan) and an ELISA kit (Shibayagi Co. Ltd, Gunma,
130 Japan), respectively. After 5 weeks administration of APCs, APCs-treated and
131 untreated ob/ob mice were fasted for 16 h, and regular insulin (2 units/kg) was injected
132 intraperitoneally. Blood glucose levels were measured at 0, 15, 30, 45, 60, 90, and 120
133 min after injection.

134

135 **Pyruvate tolerance test**

136 Pyruvate was dissolved with 0.9% (wt/vol) sterile saline. APCs-treated and
137 untreated ob/ob mice were fasted overnight for 16 h, and pyruvate (1 g/kg) was
138 injected intraperitoneally. Blood glucose levels were measured at 0, 15, 30, 60, 90, and
139 120 min after injection.¹⁶

140

141 **Calculation of homeostasis model assessment of insulin resistance**

142 The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated
143 using fasting blood glucose and insulin concentrations based on OGTT data.
144 HOMA-IR is used to estimate insulin resistance in human and animals.^{17,18} HOMA-IR

145 was calculated using the following formula:¹⁹

146 $\text{HOMA-IR} = \text{insulin (mU/L)} \times [\text{glucose (mg/dL)} / 405]$

147

148 **Measurement of body fat composition**

149 Body fat mass was measured by CT scan (LaTheta LCT-100, Aloka, Tokyo, Japan).

150 The mice were anesthetized, and the images were analyzed using LaTheta software,

151 version 1.00 and values of subcutaneous and visceral fat mass were quantified in grams

152 (g).

153

154 **Measurement of serum adiponectin**

155 Mice at the age of 16 weeks were sacrificed and blood samples were taken. Serum

156 adiponectin concentration was measured by ELISA kit (Otsuka Pharmaceutical Co. Ltd,

157 Tokyo, Japan) according to the instruction manuals.

158

159 **Histomorphology and immunohistochemistry**

160 The sections of paraffin embedding pancreas in mice at the age of 16 weeks were

161 incubated with anti-glucagon mouse monoclonal antibody (cloneK79bB10, 1:2000

162 dilution; Abcam plc, Cambridge, UK) and polyclonal rabbit anti-insulin (H-86)
163 antibody (1:100 dilution; Santa Cruz Biotechnology, Inc., Texas, U.S.A.). The sections
164 were then incubated with goat anti-mouse IgG and goat anti-rabbit
165 fluorescein-conjugated secondary antibody (1:200 dilution, Alexa Fluor 488; Alexa
166 Fluor 546; Invitrogen/Life Technologies Japan, Tokyo, Japan). Two slides randomly
167 selected from each pancreas were analyzed. After immunostaining, quantification of
168 β -cell area was performed by immunofluorescent microscope using BZ-II Analyzer
169 software (Keyence Corp., Osaka, Japan). Results are expressed as percentage of total
170 surveyed area containing cells positive for insulin. The insulin-positive cells were
171 counted as the number of islets per area of pancreas.^{20, 21}

172 Sections of liver tissues of mice at the age of 16 weeks were stained with Oil Red O
173 and Hematoxylin and Eosin (H&E). For immunohistochemistry, the liver sections were
174 incubated with anti-F4/80 rat-monoclonal antibody (1:100 dilution; Abcam plc,
175 Cambridge, UK). The sections were then treated with anti-rat fluorescein-conjugated
176 secondary antibody (Alexa Fluor 546; Invitrogen/Life Technologies Japan, Tokyo,
177 Japan) and anti-rat horseradish peroxidase (HRP)-conjugated antibody (polyclonal
178 rabbit anti-rat immunoglobulins/HRP; DakoCytomation, Glostrup, Denmark).²²

179

180 **Measurement of total cholesterol and lipid contents in liver**

181 Hepatic lipids were extracted as described previously.²³ Total cholesterol and
182 triglyceride were measured at Skylight Biotech, Inc. (Akita, Japan) using cholesterol
183 and triglyceride assay kits (cholesterol-CHO and cholesterol-TG, Sekisui Medical Co., Ltd.,
184 Tokyo, Japan). Hepatic lipid content was defined as weight per gram of liver tissue.

185

186 **Immunoblotting**

187 Liver isolated from APCs-treated and untreated ob/ob mice were lysed in ice-cold
188 lysis buffer (10 mmol/l Tris [pH 7.2], 100 mmol/l NaCl, 1 mmol/l EDTA, 1% Nonidet
189 P-40, and 0.5% sodium deoxycholate) containing protease inhibitor cocktail
190 (Complete; Roche, Mannheim, Germany), phosphatase inhibitor cocktail (Calbiochem,
191 Darmstadt, Germany), and 5 mmol/l sodium pyrophosphate. Immunoblotting was
192 performed. Primary antibodies used were rabbit anti-phospho-Akt (Ser473) and
193 anti-Akt from Cell Signaling (Danvers, MA); mouse anti-phospho-JNK and anti-JNK
194 were from Sigma (St. Louis, MO). Secondary antibodies used were horseradish
195 peroxidase-conjugated anti-rabbit and mouse antibody (GE Healthcare). Band
196 intensities were quantified with Multi Gauge software (Fujifilm, Tokyo, Japan).

197

198 **Isolation of total RNA and quantitative RT-PCR**

199 Total RNA was isolated from liver of APCs-treated mouse using Trizol (Invitrogen).
200 SYBR Green PCR Master Mix (Applied Biosystems, Foster, CA, USA) was prepared
201 for the quantitative RT-PCR run using TNF- α primer with the following sequence:
202 5'-AAATGGGCTTTCCGAATTCA-3' and 5'-CAGGGAAGAATCTGGAAAGGT-3',
203 IL-6 primer with the following sequence: 5'-GGAGGCTTAATTACACATGTT-3'
204 and 5'-TGATTTCAAGATGAATTGGAT-3', IL-1 β primer with the following
205 sequence: 5'-ATCTTTGGGGTCCGTCAACTGAPDH-3' and
206 5'-GCAACTGTTTCCTGAACTCAACT-3'. GAPDH mRNA was used as an internal
207 control. The sequences of GAPDH primer are as follows:
208 5'-AAATGGTGAAGGTCGG-3' and 5'-TCGTTGATGGCAACAA-3'. The thermal
209 cycling conditions were denaturation at 95 °C for 10 min followed by 50 cycles at
210 95 °C for 15 s and 60 °C for 1 min. mRNA levels were measured by real-time
211 quantitative RT-PCR using ABI PRISM 7000 Sequence Detection System (Applied
212 Biosystems/Life Technologies Japan, Tokyo, Japan).

213

214 **Statistical analysis**

215 The data are expressed as means \pm SE. Statistical significance was determined by
216 unpaired Student's *t*-test. $P < 0.05$ was considered significant.

217

218 **■RESULTS**

219 **Body weight, food intake, and energy expenditure**

220 We first evaluated the effect of APCs on body weight of ob/ob mice. There was no
221 difference between APCs-treated and untreated mice during the test period (Figure 2A).
222 Dietary food intake (Figure 2B) and water intake (APCs-treated mice: 6.24 ± 0.32 ml
223 of 0.5% APCs water per day, untreated mice: 7.11 ± 0.24 ml of water per day) were
224 also unchanged. Similarly, energy expenditure was not significantly different between
225 APCs-treated and untreated mice (Figure 2C).

226

227 **Glucose tolerance test and insulin tolerance test**

228 In OGTT, blood glucose levels were significantly lower at 15 min and 30 min in
229 APCs-treated ob/ob than those in untreated mice (Fig. 3A). The serum insulin levels
230 did not differ at these time points (Figure 3B). The value of HOMA-IR was

231 significantly lower in APCs-treated (27.3 ± 7.9) than that in untreated mice ($76.0 \pm$
232 13.3). In ITT, blood glucose levels were significantly lower in APCs-treated ob/ob
233 (Figure 3C). These data suggest that APCs ameliorate insulin resistance in ob/ob mice.

234 Insulin resistance contributes to an adaptive change in pancreatic β -cell mass.²⁴ We
235 therefore observed pancreatic islets morphologically by immunohistochemistry using
236 anti-insulin and anti-glucagon antibodies (Figure 3D). β -cell area was decreased by
237 21 % in APCs-treated compared with that in untreated mice (Figure 3E). On the other
238 hand, there was no difference in the number of islets (Figure 3F). These data suggest
239 that hypertrophy of pancreatic islets was suppressed by treatment of APCs.

240

241 **Effects of APCs on body composition, adipocyte size, and serum adiponectin level**

242 We then examined the effects of APCs on adipose tissue, a target organ for insulin.
243 There was no difference in lean mass and fat composition between APCs-treated and
244 untreated mice (Figure 4A). In addition, the size of adipocytes and serum adiponectin
245 levels did not change (Figure 4B and C). It is therefore unlikely that APCs have an
246 effect on insulin resistance in adipose tissue.

247

248 **Effects of APCs on hepatic insulin signals and lipid content**

249 Hepatic gluconeogenesis is enhanced in the state of insulin resistance.²⁵ In PTT,
 250 APCs-treated ob/ob mice displayed lower blood glucose levels at 15 min and 30 min
 251 after pyruvate injection, indicating that APCs treatment suppresses hepatic
 252 gluconeogenesis (Figure 5A). It was reported that Akt phosphorylation of ob/ob mice
 253 was down-regulated, indicating impairment of the insulin signaling.²⁶
 254 Insulin-stimulated Akt phosphorylation was elevated in APCs-treated compared with
 255 untreated mice (Figure 5B). Accumulation of fat in liver induces insulin resistance.²⁷
 256 We therefore estimated lipid content in liver. Interestingly, total cholesterol and TG
 257 contents in liver did not differ between APCs-treated and untreated mice (Figure 5C
 258 and D). Similarly, change of lipid content was not observed by using other methods
 259 such as H&E staining and Oil Red O staining (Figure 5E). These data indicate that
 260 APCs suppress hepatic gluconeogenesis by improving the insulin signal without
 261 altering fat accumulation in liver.

262

263 **Effects of APCs on inflammation in liver**

264 We then considered whether APCs influence inflammation in liver to ameliorate
 265 insulin resistance, and evaluated macrophage infiltration into liver by immunostaining
 266 using anti-F4/80 anti-body, a marker for mature mouse macrophage.²⁸ The number of

267 macrophage in liver was decreased in APCs-treated ob/ob mice (Figure 6A). We
268 examined the mRNA expression levels of pro-inflammatory cytokine in liver, and
269 found that mRNAs of TNF- α and IL-6 were down-regulated by APCs treatment
270 (Figure 6B). TNF- α activates TNF receptors on hepatocytes to induce JNK
271 activation.²⁹ We therefore examined JNK activation by immunoblotting using
272 anti-phospho-JNK and anti-JNK antibody. Phosphorylation of JNK was decreased by
273 APCs treatment in liver (Figure 6C). These data suggest that APCs treatment attenuates
274 inflammation in liver.

275

276 ■DISCUSSION

277 In this study, we show that oral administration of APCs ameliorates glucose
278 intolerance in obese diabetic ob/ob mice.
279 Continuous but not single (Figure S2) oral administration of APCs ameliorated glucose
280 intolerance, and suppressed the expression of inflammation-related genes and
281 phosphorylation of JNK in liver, suggesting that APCs improve insulin sensitivity in
282 liver through suppression of chronic inflammation. In our preliminary experiments, it
283 was confirmed that the dosage of 0.5% APCs in drinking water is the appropriate
284 concentration that has no effects on water intake, food intake or body weight.

285 Obesity is associated with chronic, low-grade, and systemic inflammation that may

286 contribute to the development of insulin resistance and type 2 diabetes.³⁰ Generally,
287 adipose tissue inflammation is considered to initiate adipocyte hypertrophy and
288 hyperplasia and to influence release of adipocytokines and pro-inflammatory signaling.
289 On the other hand, obesity also is associated with the regulation of adipocytokine
290 secretion, and causes adverse effects on inflammation and insulin sensitivity.³¹
291 Akiyama reported that apple proanthocyanidins do not affect body weight or food
292 intake in W/W^V and B10A mice.³² There are several reports suggesting that
293 procyanidins improve glycemic control.³³ In accord with these data, while the body
294 weight, food intake, and fat mass of APCs-treated ob/ob mice were unchanged
295 compared with those of untreated mice, the insulin sensitivity was significantly
296 improved in our study.

297 The beneficial effects of procyanidins from various plants have been investigated.
298 Procyanidin from cinnamon was reported to lower levels of blood glucose, total
299 cholesterol, low-density cholesterol, and hemoglobin A1c in type 2 diabetes.³³
300 Persimmon peel proanthocyanidins decrease blood glucose levels and glycosylated
301 protein concentrations and have a protective effect against diabetes-induced oxidative
302 stress in streptozotocin-induced diabetic rats.³⁴ Recently, tetrameric procyanidins from
303 cacao liquor were shown to increase the levels of plasma glucagon-like peptide-1

(GLP-1), an incretin hormone that potentiates insulin secretion.³⁵ Our data showing that APCs ameliorate impaired hepatic insulin signaling in ob/ob mice may be useful in clarifying the therapeutical actions of substances from vegetables and fruits.

Hepatic insulin resistance is a key feature of obesity-related type 2 diabetes.³⁶ Kupffer cells, which are liver-resident macrophage-like cells, are activated by inflammation, apoptosis, and necrosis of hepatocytes. Activation of Kupffer cells causes the release of inflammatory cytokines such as TNF- α and IL-6 in liver.³⁷ It is reported that accumulation of fat in hepatocyte induces inflammation in liver.³⁸ However, APCs treatment decreased the number of macrophages and the expression levels of TNF- α and IL-6 in liver without changing the lipid content in the liver of ob/ob mice. These data suggest that the effect of APCs on liver inflammation is not due to suppression of fat accumulation in hepatocytes.

It was suggested that intestinal bacteria may contribute to the pathogenesis of inflammation in liver. Lipopolysaccharide (LPS), one of the gut-derived endotoxins, was reported to cause liver damage via activation of Kupffer cells and release of TNF- α and other cytokines.³⁹ Obesity alters the ecology of intestinal microbiota.⁴⁰ It is reported that ob/ob mice have higher endotoxin levels in the portal blood than that in wild-type mice.⁴¹ Recent studies suggested that procyanidins can be degraded by some

322 kinds of intestinal microbiota⁴² and also that administration of apple flavonoid alters
 323 intestinal microbiota.⁴³ In addition to our preliminary experiment using ob/ob mouse
 324 (data not shown), we have carried out an experiment whether APCs could change the
 325 microbiota of high-fat/high-sucrose (HFHS)-fed C57BL/6J male mice.⁴⁴ We found the
 326 chronic oral administration of high polymeric APCs prevent obesity associated with
 327 gut microbial and metabolic changes. It is therefore possible that APCs suppress
 328 inflammation in liver not by decreasing fat accumulation but through effects on
 329 intestinal microbiota. Glycolysis, gluconeogenesis, glycogenolysis and glycogen
 330 synthesis is involved in the maintenance of blood glucose levels.⁴⁵ Both
 331 gluconeogenesis and glycogenolysis are important in glucose production in liver.
 332 Pyruvate is one of well-known substances of gluconeogenesis. In this study, we
 333 showed APCs are considered to be suppress pyruvate induced gluconeogenesis (Figure
 334 5A). However, the effect of APCs on glycogen metabolism is not clear. Further studies
 335 are needed to clarified the details of how APCs ameliorate glucose resistance in
 336 diabetic state.

337 In conclusion, our data indicate that oral administration of APCs ameliorates insulin
 338 resistance by improving hepatic insulin signaling through suppression of inflammation
 339 in ob/ob mice. Moreover, further investigation of the mechanism of the effects of APCs

340 on glucose metabolism could shed light on the pathophysiology of insulin resistance
341 and suggest new targets for type 2 diabetes therapy.

342

343 ■AUTHOR INFORMATION

344 Corresponding Author

345 * Phone: +81(Japan)-75-751-3560

346 E-mail: nagasima@kuhp.kyoto-u.ac.jp

347

348 Funding

349 This work was supported by Grants for research project (Development of Fundamental
350 Technology for Analysis and Evaluation of Functional Agricultural Products and
351 Functional Foods; Development of Agricultural Products and Foods with
352 Health-promoting Benefits) from the Ministry of Agriculture, Forestry and Fisheries of
353 Japan and Scientific Research Grants from the Ministry of Education, Culture, Sports,
354 Science and Technology of Japan.

355

356 Notes

357 The authors declare no competing financial interest.

■ACKNOWLEDGMENTS

We thank Sara Yasui and Mai Akazawa for technical assistance. We gratefully acknowledge Yuko Ono for the preparation of APCs for this research. K.O. and T.S. conducted the experiments; K.O., M.O., and K.N. wrote the manuscript; Y.S., Y.T., G.Y., H.S., K.S., N.F., H.T., R.U., and E.M. analyzed and evaluated the data; K.N., S.F., and N.I. planned the research, analyzed the data, and edited the manuscript. All authors read and approved the final manuscript.

■ABBREVIATIONS USED

APCs (apple procyanidins), OGTT (oral glucose tolerance test), ITT (insulin tolerance test), PTT (pyruvate tolerance test), TNF (tumor necrosis factor), IL (interleukin), JNK (c-Jun N-terminal kinase), IRS (insulin receptor substrate), SGLT (sodium glucose cotransporter), HOMA-IR (homeostasis model assessment of insulin resistance), GLP (glucagon-like peptide)

■REFERENCES

- (1) Rudich, A.; Tirosh, A.; Potashnik, R.; Hemi, R.; Kanety, H.; Bashan, N. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes.

- Diabetes* **1998**, *47*, 1562-1569.
- (2) Tiganis, T. Reactive oxygen species and insulin resistance: the good, the bad and the ugly. *Trends in Pharmacol. Sci.* **2011**, *32*, 82-89.
- (3) Hung, H. C.; Joshipura, K. J.; Jiang, R.; Hu, F. B.; Hunter, D.; Smith-Warner, S. A.; Colditz, G. A.; Rosner, B.; Spiegelman, D.; Willett, W. C. Fruit and vegetable intake and risk of major chronic disease. *J. Natl. Cancer Institute.* **2004**, *96*, 1577-1584.
- (4) Muraki, I.; Imamura, F.; Manson, J. E.; Hu, F. B.; Willett, W. C.; van Dam, R. M.; Sun, Q. Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies. *BMJ* **2013**, *347*, f5001.
- (5) Leontowicz, H.; Gorinstein, S.; Lojek, A.; Leontowicz, M.; Ci, z, M.; Soliva-Fortuny, R.; Park, Y. S.; Jung, S. T.; Trakhtenberg, S.; Martin-Belloso, O. Comparative content of some bioactive compounds in apples, peaches and pears and their influence on lipids and antioxidant capacity in rats. *J. Nutr. Biochem.* **2002**, *13*, 603-610.
- (6) Jung, M.; Triebel, S.; Anke, T.; Richling, E.; Erkel, G. Influence of apple polyphenols on inflammatory gene expression. *Mol. Nutr. Food Res.* **2009**, *53*, 1263-1280.
- (7) Lapidot, T.; Walker, M. D.; Kanner, J. Can apple antioxidants inhibit tumor cell proliferation? Generation of H₂O₂ during interaction of phenolic compounds with

- cell culture media. *J. Agric. Food Chem.* **2002**, *50*, 3156-3160.
- (8) Shoji, T.; Mutsuga, M.; Nakamura, T.; Kanda, T.; Akiyama, H.; Goda, Y. Isolation and structural elucidation of some procyanidins from apple by low-temperature nuclear magnetic resonance. *J. Agric. Food Chem.* **2003**, *51*, 3806-3813.
- (9) Vayndorf, E. M.; Lee, S. S.; Liu, R. H. Whole apple extracts increase lifespan, healthspan and resistance to stress in *Caenorhabditis elegans*. *J. Funct. Foods*, **2013**, *5*, 1236-1243.
- (10) Sugiyama, H.; Akazome, Y.; Shoji, T.; Yamaguchi, A.; Yasue, M.; Kanda, T.; Ohtake, Y. Oligomeric procyanidins in apple polyphenol are main active components for inhibition of pancreatic lipase and triglyceride absorption. *J. Agric. Food Chem.* **2007**, *55*, 4604-4609.
- (11) Yoshioka, Y.; Akiyama, H.; Nakano, M.; Shoji, T.; Kanda, T.; Ohtake, Y.; Takita, T.; Matsuda, R.; Maitani, T. Orally administered apple procyanidins protect against experimental inflammatory bowel disease in mice. *Int. Immunopharmacol.* **2008**, *8*, 1802-1807.
- (12) Yanagida, A.; Kanda, T.; Takahashi, T.; Kamimura, A.; Hamazono, T.; Honda, S. Fractionation of apple procyanidins according to their degree of polymerization by normal-phase high-performance liquid chromatography. *J. Chromatogr. A*. **2000**, *890*,

251-259.

- (13) Kahn, B. B.; Shulman, G. I.; DeFronzo, R. A.; Cushman, S. W.; Rossetti, L.

Normalization of blood glucose in diabetic rats with phlorizin treatment reverses

insulin-resistant glucose transport in adipose cells without restoring glucose

transporter gene expression. *J. Clin. Invest.* **1991**, *87*, 561-570.

- (14) Bagdas, D.; Etoz, B. C.; Gul, Z.; Ziyank, S.; Inan, S.; Turacozen, O.; Gul, N. Y.;

Topal, A.; Cinkilic, N.; Tas, S.; Ozyigit, M. O.; Gurun, M. S. In vivo systemic

chlorogenic acid therapy under diabetic conditions: Wound healing effects and

cytotoxicity/genotoxicity profile. *Food Chem. Toxicol.* **2015**, *81*, 54-61.

- (15) Onakpoya, I. J.; Spencer, E. A.; Thompson, M. J.; Heneghan, C. J. The effect of

chlorogenic acid on blood pressure: a systematic review and meta-analysis of

randomized clinical trials. *J. Hum. Hypertens.* **2015**, *29*, 77-81.

- (16) Robertson, K.; Lu, Y.; De Jesus, K.; Li, B.; Su, Q.; Lund, PK.; Liu, JL. A

general and islet cell-enriched overexpression of IGF-I results in normal islet cell

growth, hypoglycemia, and significant resistance to experimental diabetes. *Am J*

Physiol Endocrinol Metab. **2008**, *294*, E928-38.

- (17) Konrad, D.; Rudich, A.; Schoenle, E. J. Improved glucose tolerance in mice

receiving intraperitoneal transplantation of normal fat tissue. *Diabetologia* **2007**, *50*,

833-839.

- (18) Matthews, D. R.; Hosker, J. P.; Rudenski, A. S.; Naylor, B. A.; Treacher, D. F.; Turner, R. C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* **1985**, *28*, 412-419.
- (19) Mlinar, B.; Marc, J.; Janez, A.; Pfeifer, M. Molecular mechanisms of insulin resistance and associated diseases. *Clin. Chim. Acta.* **2007**, *375*, 20-35.
- (20) Fløyel, T.; Brorsson, C.; Nielsen, LB.; Miani, M.; Bang-Berthelsen, CH.; Friedrichsen, M.; Overgaard, AJ.; Berchtold, LA.; Wiberg, A.; Poulsen, P.; Hansen, L.; Rosinger, S.; Boehm, BO.; Ram, R.; Nguyen, Q.; Mehta, M.; Morahan, G.; Concannon, P.; Bergholdt, R.; Nielsen, JH.; Reinheckel, T.; von Herrath, M.; Vaag, A.; Eizirik, DL.; Mortensen, HB.; Størling, J.; Pociot, F. CTSH regulates β -cell function and disease progression in newly diagnosed type 1 diabetes patients. *Proc Natl Acad Sci U S A.* **2014**, *111*, 10305-10310.
- (21) Nasteska, D.; Harada, N.; Suzuki, K.; Yamane, S.; Hamasaki, A.; Joo, E.; Iwasaki, K.; Shibue, K.; Harada, T.; Inagaki, N. Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. *Diabetes.* **2014**, *63*, 2332-2343.

- (22) Kuroda, N.; Inoue, K.; Ikeda, T.; Hara, Y.; Wake, K.; Sato, T.

Apoptotic response through a high mobility box 1 protein-dependent mechanism in

LPS/GalN-induced mouse liver failure and glycyrrhizin-mediated inhibition. *PLoS*

One **2014**, 9, e92884.
- (23) Folch, J.; Lees, M.; Sloane Stanley, G. H. A simple method for the isolation and

purification of total lipides from animal tissues. *J. Biol.Chem.* **1957**, 226, 497-509.
- (24) Mezza, T.; Muscogiuri, G.; Sorice, G. P.; Clemente, G.; Hu, J.; Pontecorvi, A.;

Holst, J. J.; Giaccari, A.; Kulkarni, R. N. Insulin resistance alters islet morphology

in nondiabetic humans. *Diabetes* **2014**, 63, 994-1007.
- (25) Wahren, J.; Ekberg, K. Splanchnic regulation of glucose production. *Annu. Rev.*

Nutr. **2007**, 27, 329-345.
- (26) Standaert, M. L.; Sajan, M. P.; Miura, A.; Kanoh, Y.; Chen, H. C.; Farese, R. V.;

Jr., Farese, R. V. Insulin-induced activation of atypical protein kinase C, but not

protein kinase B, is maintained in diabetic (ob/ob and Goto-Kakazaki) liver.

Contrasting insulin signaling patterns in liver versus muscle define phenotypes of

type 2 diabetic and high fat-induced insulin-resistant states. *J. Biol.Chem.* **2004**, 279,

24929-24934.
- (27) Samuel, V. T.; Liu, Z. X.; Qu, X.; Elder, B. D.; Bilz, S.; Befroy, D.; Romanelli, A.

- J.; Shulman, G. I. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. *J. Biol. Chem.* **2004**, *279*, 32345-32353.
- (28) Baratta, J. L.; Ngo, A.; Lopez, B.; Kasabwalla, N.; Longmuir, K. J.; Robertson, R. T. Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine structural analysis. *Histochem. Cell Biol.* **2009**, *131*, 713-726.
- (29) Schwabe, R. F.; Brenner, D. A. Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. *Am. J. Physiol. Gastroint. Liver Physiol.* **2006**, *290*, G583-589.
- (30) Jimenez-Gomez, Y.; Mattison, J. A.; Pearson, K. J.; Martin-Montalvo, A.; Palacios, H. H.; Sossong, A. M.; Ward, T. M.; Younts, C. M.; Lewis, K.; Allard, J. S.; Longo, D. L.; Belman, J. P.; Malagon, M. M.; Navas, P.; Sanghvi, M.; Moaddel, R.; Tilmont, E. M.; Herbert, R. L.; Morrell, C. H.; Egan, J. M.; Baur, J. A.; Ferrucci, L.; Bogan, J. S.; Bernier, M.; de Cabo, R. Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. *Cell Metab.* **2013**, *18*, 533-545.
- (31) de Luca, C.; Olefsky, J. M. Inflammation and insulin resistance. *FEBS Lett.* **2008**, *582*, 97-105.

- (32) Akiyama, H.; Sato, Y.; Watanabe, T.; Nagaoka, M. H.; Yoshioka, Y.; Shoji, T.; Kanda, T.; Yamada, K.; Totsuka, M.; Teshima, R.; Sawada, J.; Goda, Y.; Maitani, T. Dietary unripe apple polyphenol inhibits the development of food allergies in murine models. *FEBS Lett.* **2005**, *579*, 4485-4491.
- (33) Qin, B.; Panickar, K. S.; Anderson, R. A. Cinnamon: potential role in the prevention of insulin resistance, metabolic syndrome, and type 2 diabetes. *J. Diabetes Sci. Technol.* **2010**, *4*, 685-693.
- (34) Lee, Y. A.; Kim, Y. J.; Cho, E. J.; Yokozawa, T. Ameliorative effects of proanthocyanidin on oxidative stress and inflammation in streptozotocin-induced diabetic rats. *J. Agric. Food Chem.* **2007**, *55*, 9395-9400.
- (35) Yamashita, Y.; Okabe, M.; Natsume, M.; Ashida, H. Cinnamtannin A2, a tetrameric procyanidin, increases GLP-1 and insulin secretion in mice. *Biosci. Biotechnol. Biochem.* **2013**, *77*, 888-891.
- (36) Perseghin, G. Viewpoints on the way to a consensus session: where does insulin resistance start? The liver. *Diabetes Care* **2009**, *32 Suppl 2*, S164-167.
- (37) Dixon, L. J.; Barnes, M.; Tang, H.; Pritchard, M. T.; Nagy, L. E. Kupffer cells in the liver. *Comprehensive Physiol.* **2013**, *3*, 785-797.
- (38) Michelotti, G. A.; Machado, M. V.; Diehl, A. M. NAFLD, NASH and liver

- cancer. *Nat. Rev. Gastroenterol. Hepatol.* **2013**, *10*, 656-665.
- (39) Luedde, T.; Schwabe, R. F. NF-kappaB in the liver--linking injury, fibrosis and hepatocellular carcinoma. *Nat. Rev. Gastroenterol. Hepatol.* **2011**, *8*, 108-118.
- (40) Ley, R. E.; Backhed, F.; Turnbaugh, P.; Lozupone, C. A.; Knight, R. D.; Gordon, J. I. Obesity alters gut microbial ecology. *Proc. Natl. Acad. Sci. U S A*, **2005**, *102*, 11070-11075.
- (41) Brun, P.; Castagliuolo, I.; Di Leo, V.; Buda, A.; Pinzani, M.; Palu, G.; Martines, D. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. *Am. J. Physiol. Gastroint. Liver Physiol.* **2007**, *292*, G518-525.
- (42) Ou, K.; Sarnoski, P.; Schneider, K. R.; Song, K.; Khoo, C.; Gu, L.. Microbial catabolism of procyanidins by human gut microbiota. *Mol. Nutr. Food Res.* **2014**, *58*, 2196-2205.
- (43) Espley, R. V.; Butts, C. A.; Laing, W. A.; Martell, S.; Smith, H.; McGhie, T. K.; Zhang, J.; Paturi, G.; Hedderley, D.; Bovy, A.; Schouten, H. J.; Putterill, J.; Allan, A. C.; Hellens, R. P. Dietary flavonoids from modified apple reduce inflammation markers and modulate gut microbiota in mice. *J. Nutr.* **2014**, *144*, 146-154.
- (44) Masumoto, S.; Terao, A.; Yamamoto, Y.; Mukai, T.; Miura, T.; Shoji, T.

Non-absorbable apple procyanidins prevent obesity associated with gut microbial and metabolomic changes. *Sci Rep.* **2016**, *6*: 31208.

- (45) Corssmit, EP.; Romijn, JA.; Sauerwein, HP. Regulation of glucose production with special attention to nonclassical regulatory mechanisms: a review. *Metabolism.* **2001**, *50*,742-55.

Figure Legends

Figure 1

Reversed phase HPLC profile of apple polyphenol (upper) and apple procyanidins (lower). These panels show that our apple procyanidins do not include chlorogen acid or phloretin glucoside (Phlorizin) fractions, which are included as apple polyphenols.

Figure 2

Effects of APCs administration on body weight, food intake, and energy expenditure in ob/ob mice. (A) Body weight (n=12) and (B) food intake (n=12) were measured once every week. (C) Energy expenditure (n=4) was measured for 48 h. APCs (-) and APCs (+) indicate APCs-untreated and APCs-treated ob/ob mice, respectively. Results are presented as mean \pm SE. * P <0.05

Figure 3

Effects of APCs administration on OGTT, ITT, and pancreatic islet size in ob/ob mice.

(A) Blood glucose levels and (B) serum insulin levels were measured during OGTT (load of glucose 1g/kg body weight). (C) Blood glucose levels measured during ITT (load of insulin 2U/kg body weight) (D) immunocytochemistry of pancreatic islets. (E) β -cell area in the total pancreatic area (n=4) and (F) the number of islets per area of pancreas (n=4). APCs (-) and APCs (+) indicate APCs-untreated and APCs-treated ob/ob mice, respectively. Results are presented as mean \pm SE. * P <0.05

Figure 4

Effects of APCs administration on adipose tissue adipocyte size and serum adiponectin level in ob/ob mice. (A) Visceral, subcutaneous, and total fat mass in APCs-treated and untreated mice were measured using CT images of transverse abdominal sections (n=4). (B) Representative images of HE staining of adipose tissue section. (C) Serum adiponectin concentrations (n=8). APCs (-) and APCs (+) indicate APCs-untreated and treated ob/ob mice, respectively. Results are presented as mean \pm SE.

Figure 5

Effects of APCs administration on liver tissue in ob/ob mice. (A) Glucose levels measured during PTT (load of pyruvate 1g/kg body weight, n=8) (B) The ratio of phosphorylated Akt to total Akt (t-Akt) in liver tissues (n=3). (C) Total cholesterol (n=4) level and (D) triglycerides level in liver were measured (n=4). (E) HE and Oil red O staining of the liver. APCs (-) and APCs (+) indicate APCs-untreated and treated ob/ob mice, respectively. Results are presented as mean \pm SE. * P <0.05

Figure 6

Effects of APCs administration on liver inflammation in ob/ob mice. (A) Immunohistochemistry with anti-F4/80 antibody in liver of APCs-treated and untreated mice. Arrows indicate representative macrophages in liver. (B) mRNA levels of TNF- α , IL-6, and IL-1 β in the liver (n=8). (C) Effects of APCs administration on the ratio of phosphorylated JNK to total JNK (t-JNK) in liver in ob/ob mice (n=3). APCs (-) and APCs (+) indicate APCs-treated and untreated ob/ob mice, respectively. Results are presented as mean \pm SE.

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5






FIGURE 6





Ameliorate insulin resistance via suppression of pro-inflammatory cytokines expression in liver

